UBS AM’s Minerva Neurosciences NERV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.11K Buy
+629
New +$2.7K ﹤0.01% 4035
2019
Q4
– Sell
-4,608
Closed -$286K – 2733
2019
Q3
$286K Buy
4,608
+1,308
+40% +$74.1K ﹤0.01% 2473
2019
Q2
$149K Hold
3,300
– – ﹤0.01% 2605
2019
Q1
$208K Hold
3,300
– – ﹤0.01% 2440
2018
Q4
$178K Hold
3,300
– – ﹤0.01% 2421
2018
Q3
$331K Hold
3,300
– – ﹤0.01% 2242
2018
Q2
$218K Hold
3,300
– – ﹤0.01% 2444
2018
Q1
$165K Buy
3,300
+762
+30% +$36.6K ﹤0.01% 2415
2017
Q4
$123K Hold
2,538
– – ﹤0.01% 2382
2017
Q3
$154K Buy
+2,538
New +$146K ﹤0.01% 2315

Other funds holding NERV

UBS AM's NERV Position: Q3 2026 in Review

UBS AM opened a new position in Minerva Neurosciences (NERV) in Q3 2026: 629 shares worth $2.11K. The stake represents ﹤0.01% of the portfolio and ranks #4035 among its holdings. This is a return to the name: UBS AM previously reported a position in NERV as recently as Q3 2019.

UBS AM first reported a position in NERV in Q3 2017 and has held it in 10 quarters since. The position peaked at $331K in Q3 2018. 54 funds tracked by Wall St. Rank hold NERV as of Q3 2026.

  • UBS AM held 629 shares of Minerva Neurosciences worth $2.11K as of Q3 2026.
  • Minerva Neurosciences was a new UBS AM position in Q3 2026.
  • Minerva Neurosciences made up ﹤0.01% of UBS AM's portfolio in Q3 2026, its #4035 holding.
  • UBS AM first reported a position in Minerva Neurosciences in Q3 2017 and has held it in 10 quarters since.
  • UBS AM's Minerva Neurosciences position peaked at $331K in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q3 2026.

Based on UBS AM's 13F filing for Q3 2026, filed 16 Nov 2026.